Parabilis Medicines raises $670.0M IPO (United States, Jun 2026)

Parabilis sets a record with a $670M biotech IPO - BioPharma Dive

Parabilis Medicines is a biotechnology startup focused on developing therapies for 'undruggable' targets, particularly in cancer treatment. The company has raised significant funding to advance its innovative peptide drugs, known as 'Helicons', which aim to target difficult-to-reach cancer-driving proteins. Their most advanced candidate, zolucatetide, is set to enter Phase 3 trials for desmoid tumors in 2027.

Parabilis sets a record with a $670M biotech IPO  BioPharma Dive